Genmab (CPSE:GMAB) - 주가, 뉴스 및 분석

GMAB 주식 개요

젠맙 A/S는 주로 덴마크에서 암 및 기타 질병 치료를 위한 항체 치료제를 개발하는 회사입니다. 자세한 내용

GMAB 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	4/6
과거 실적	4/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 84.5% 에서 거래

수익은 매년 23.73% 증가할 것으로 예상됩니다.

지난 1년간 수익이 12.9% 증가했습니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

위험 검사에서 GMAB 에 대한 위험이 감지되지 않았습니다.

Genmab A/S 경쟁사

Bavarian Nordic

CPSE:BAVA

DKK 13.3b

H. Lundbeck

CPSE:HLUN B

DKK 42.7b

ALK-Abelló

CPSE:ALK B

DKK 34.9b

Neurocrine Biosciences

NasdaqGS:NBIX

US$11.9b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Genmab
과거 주가
현재 주가	DKK 1,463.50
52주 최고치	DKK 2,283.00
52주 최저치	DKK 1,450.00
베타	0.86
11개월 변경	-6.40%
3개월 변경 사항	-19.61%
1년 변경 사항	-34.08%
33년 변화	-44.59%
5년 변화	-6.52%
IPO 이후 변화	528.11%

최근 뉴스 및 업데이트

The Price Is Right For Genmab A/S (CPH:GMAB)

Sep 19

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Aug 22

Recent updates

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Feb 21

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Nov 13

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Jun 19

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

May 29

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Mar 18

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 27

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Dec 17

주주 수익률

	GMAB	DK Biotechs	DK 마켓
7D	-9.0%	-11.8%	-3.1%
1Y	-34.1%	-10.0%	5.7%

수익률 대 산업: GMAB 지난 1년 동안 -10 %를 반환한 Danish Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: GMAB 지난 1년 동안 5.7 %를 반환한 Danish 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is GMAB's price volatile compared to industry and market?
GMAB volatility
GMAB Average Weekly Movement	3.3%
Biotechs Industry Average Movement	7.8%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

안정적인 주가: GMAB 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: GMAB 의 주간 변동성( 3% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1999	2,635	Jan G.J. de Winkel	www.genmab.com

젠맙 A/S는 주로 덴마크에서 암 및 기타 질병 치료를 위한 항체 치료제를 개발합니다. 이 회사는 다발성 골수종(MM) 환자 치료를 위한 인간 단일 클론 항체인 다잘렉스(DARZALEX), 갑상선 안질환 치료를 위한 테프로투무맙, 진행성 또는 전이성 위암 또는 식도암과 비소세포폐암을 위한 아미반타맙을 판매하고 있습니다. 다라투무맙은 다발골수성 백혈병, 비다발골수성 백혈병 및 AL 아밀로이드증 치료제로, GEN1047, 티소투맙 베도틴은 자궁경부암, 난소암 및 고형암 치료제로, 듀오바디-PD-L1x4-1BB 및 듀오바디-CD40x4-1BB는 고형 종양 치료제로 사용됩니다; 재발성/불응성 미만성 거대 B세포 림프종 및 만성 림프구성 백혈병 치료를 위한 엡코리타맙, 혈액암 치료를 위한 HexaBody-CD38 및 GEN3017.

Genmab A/S 기본 사항 요약

Genmab 의 수익과 매출은 시가총액과 어떻게 비교하나요?
GMAB 기본 통계
시가총액	DKK 92.09b
수익(TTM)	DKK 4.70b
수익(TTM)	DKK 19.84b

19.8x

P/E 비율

4.7x

P/S 비율

GMAB 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
GMAB 손익 계산서(TTM)
수익	DKK 19.84b
수익 비용	DKK 774.00m
총 이익	DKK 19.07b
기타 비용	DKK 14.37b
수익	DKK 4.70b

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	74.03
총 마진	96.10%
순이익 마진	23.69%
부채/자본 비율	0%

GMAB 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

GMAB 주식 개요

보상

위험 분석

Genmab A/S 경쟁사

CPSE:BAVA

DKK 13.3b

CPSE:HLUN B

DKK 42.7b

CPSE:ALK B

DKK 34.9b

NasdaqGS:NBIX

US$11.9b

가격 내역 및 성능

최근 뉴스 및 업데이트

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind